Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN C R 900 300 versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN C R 900 300 versus VEETIDS 125.
BICILLIN C-R 900/300 vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine and penicillin G procaine are beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis via autolytic enzymes. Synergistic action covers both susceptible Gram-positive cocci (e.g., Streptococcus pyogenes) and some Gram-negative cocci (e.g., Neisseria spp.).
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Intramuscular injection: 1.2 mL (900,000 units penicillin G benzathine and 300,000 units penicillin G procaine) every 48 hours for 3 doses; for severe infections, up to 2.4 mL (1,800,000/600,000 units) as a single dose.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
0.5-1 hour for penicillin G; prolonged to 3-6 hours in renal impairment. Procaine component has no significant effect on elimination half-life
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Renal: 60-90% as unchanged drug; biliary/fecal: minor (less than 10%)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic